Actions and Spectrum:
capmatinib is a selective inhibitor of the MET receptor tyrosine kinase. The MET receptor plays a role in cell growth, survival, and invasion, and it can be overactivated in certain types of cancer, including NSCLC. capmatinib works by binding to the MET receptor and inhibiting its activity, disrupting the signaling pathways contributing to cancer growth and spread. By targeting this specific pathway, capmatinib aims to inhibit the growth and progression of MET-driven cancers.
capmatinib is specifically indicated for treating metastatic NSCLC with a mutation known as MET exon 14 skipping mutation. This mutation leads to abnormal MET receptor activity and is associated with a more aggressive form of NSCLC. It targets this specific genetic alteration and inhibits the abnormal signaling that drives cancer growth in patients with this mutation.
